Q1 Earnings Forecast for Indivior Issued By Northland Capmk

Indivior PLC (NASDAQ:INDV) – Research analysts at Northland Capmk issued their Q1 2026 EPS estimates for Indivior in a research report issued on Tuesday, January 20th. Northland Capmk analyst C. Byrnes expects that the company will earn $0.61 per share for the quarter. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. Northland Capmk also issued estimates for Indivior’s Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.69 EPS and FY2027 earnings at $3.10 EPS.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%.

Other analysts have also issued reports about the company. HC Wainwright raised their target price on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Morgan Stanley restated an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $36.00.

Indivior Stock Performance

Shares of INDV opened at $32.95 on Wednesday. The stock has a fifty day moving average price of $34.41 and a two-hundred day moving average price of $26.95. Indivior has a 52-week low of $7.62 and a 52-week high of $38.00. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 35.82 and a beta of 0.75.

Institutional Trading of Indivior

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its position in shares of Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Jane Street Group LLC increased its holdings in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after purchasing an additional 958,132 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in Indivior in the second quarter valued at about $262,000. Finally, Y Intercept Hong Kong Ltd boosted its holdings in Indivior by 17.4% during the second quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after buying an additional 3,769 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Insider Activity

In other Indivior news, Director Barbara Ryan bought 775 shares of the business’s stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 1,963 shares in the company, valued at approximately $69,470.57. This trade represents a 65.24% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David E. Wheadon bought 1,771 shares of Indivior stock in a transaction dated Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the purchase, the director directly owned 14,395 shares in the company, valued at approximately $509,439.05. The trade was a 14.03% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 4,871 shares of company stock worth $172,385.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.